GeneDx Holdings Corp. Forecasted to Post Q1 2024 Earnings of ($0.03) Per Share (NASDAQ:WGS)

GeneDx Holdings Corp. (NASDAQ:WGSGet Rating) – Research analysts at Jefferies Financial Group issued their Q1 2024 EPS estimates for GeneDx in a report released on Wednesday, March 15th. Jefferies Financial Group analyst B. Couillard expects that the company will post earnings per share of ($0.03) for the quarter. The consensus estimate for GeneDx’s current full-year earnings is ($0.53) per share. Jefferies Financial Group also issued estimates for GeneDx’s Q2 2024 earnings at ($0.04) EPS, Q3 2024 earnings at ($0.04) EPS and Q4 2024 earnings at ($0.04) EPS.

GeneDx Stock Performance

WGS stock opened at $0.35 on Thursday. The company has a current ratio of 1.89, a quick ratio of 1.62 and a debt-to-equity ratio of 0.02. GeneDx has a twelve month low of $0.22 and a twelve month high of $3.28. The business’s 50 day moving average is $0.43. The firm has a market capitalization of $137.00 million, a PE ratio of -0.38 and a beta of 2.01.

Insiders Place Their Bets

In other news, CEO Katherine Stueland sold 92,644 shares of GeneDx stock in a transaction on Friday, March 10th. The shares were sold at an average price of $0.36, for a total value of $33,351.84. Following the transaction, the chief executive officer now directly owns 308,574 shares of the company’s stock, valued at approximately $111,086.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 157,307 shares of company stock valued at $56,631.

About GeneDx

(Get Rating)

Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.

See Also

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with's FREE daily email newsletter.